fb2 Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis Number 96 - Online indir

XML tabanlı FB2 Rusya'da yaşama başladı. E-kitap koleksiyoncuları arasında, meta verileri indirme dosyasında Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis Number 96 saklayabildiği için yaygındır. Ayrıca, diğer biçimlere dönüştürme kolaylığı nedeniyle yaygın olarak bir depolama biçimi olarak kullanılır. FB2, Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis Number 96 tarafından Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis Number 96 adlı kitabın her bir öğesini tanımlayan ve öncelikle kurguya yönelik XML içerir. FB2 dosyaları Windows, macOS ve Linux için çeşitli e-kitap okuyucuları tarafından görüntülenebilir. FB2 dosya biçimi kitabın görünümü yerine yapısını tanımlar. Bu, diğer biçimlere dönüştürme ve ücretsiz Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis Number 96 indirme için kullanışlı hale getirir. Biçim, basit anlamsal işaretleme, meta verileri gömme, Unicode ve yerleşik biçimlendirme ile ayırt edilir. Bu biçim, tüm cihazlarla ve biçimlerle uyumluluk sağlamak üzere tasarlanmıştır. FB2'nin özelliği, fb2'nin donanıma bağlı olmaması ve herhangi bir kağıt boyutuna sahip olmamasıdır, FB2'de herhangi bir yerde hiçbir ölçü birimi belirtilmez - piksel, nokta veya boyut. Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis Number 96 U. S. Department of Health and Human Services .Fb2 dosyasından alınan metnin nasıl görüneceği, bu biçimin görüntüleme programının ayarlarına veya dosyayı başka bir biçime dönüştürürken belirtilen parametrelere bağlıdır. Bu formatın dezavantajı, ders kitapları, referans kitaplar ve bilimsel yayınlar için anlamlılık eksikliğidir (hatta “sanat kitabı” adı bundan söz eder). Biçimdeki metnin karmaşık bir düzeni, numaralı ve madde işaretli listeler ve diğer özel araçlar için destek yoktur. Tanınmış e-kitapların birçoğu FB2'yi yalnızca harici yazılım aracılığıyla destekler; PocketBook ve ABC gibi Sovyet sonrası ülkelerden gelen gelişmeler başlangıçta FB2'yi okuyor.

The purpose of this report is to update a previous evidence review commissioned by the U.S. Preventive Services Task Force (USPSTF) on screening for asymptomatic HIV infection in pregnant women, including adolescents. In 2005, based on the earlier review, the USPSTF recommended that clinicians screen all pregnant women for HIV (grade A recommendation). Although the USPSTF found no studies that directly evaluated prenatal HIV screening versus no screening on risk of mother-to-child transmission or other clinical outcomes, it found good evidence that prenatal testing is accurate and acceptable to women and that treatment with recommended interventions (combination antiretrovirals, elective Cesarean delivery in women with viral loads greater than 1,000 copies/mL near the time of delivery, and avoidance of breastfeeding) is associated with major reductions in risk of mother-to-child transmission (from 14% to 25% in untreated women to 1% to 2% with treatment). The USPSTF concluded that benefits of treatments in reducing perinatal transmission substantially outweighed short-term harms, though evidence on long-term maternal or infant harms associated with screening and subsequent interventions was limited. The current report will be used by the USPSTF to update its 2005 recommendation on prenatal HIV screening. This update focuses on newer evidence on the accuracy and acceptability of rapid versus standard testing, the effectiveness of newer antiretroviral regimens for reducing mother-to-child transmission, long-term maternal outcomes following use of antiretroviral regimens during pregnancy, and maternal and infant harms associated with use of antiretroviral medications. Because perinatal practices and interventions related to prevention of HIV infection are substantially impacted by the availability of resources, the report will emphasize evidence applicable to typical practice in the United States. A major goal of prenatal screening for HIV is to reduce the risk of mother-to-child transmission through subsequent interventions. Other important goals are to improve long-term clinical outcomes in HIV-infected women, facilitate early identification of infected newborns, help women to make more informed future reproductive choices, and reduce risk of horizontal transmission through effects on risky behaviors. Using the methods developed by the USPSTF, the USPSTF and the Agency for Healthcare Research and Quality (AHRQ) determined the scope and key questions for this review. Investigators created an analytic framework with the key questions and patient populations, interventions, and outcomes reviewed. The target population for HIV screening was pregnant women without signs or symptoms of HIV infection. Key Questions include: Key Question 1. What are the benefits of HIV screening versus no screening in asymptomatic pregnant women on maternal or child morbidity, mortality, or quality of life or rates of mother-to-child transmission? Key Question 2a. What is the yield (number of new diagnoses) of repeat HIV screening in asymptomatic pregnant women? Key Question 2b. What are the adverse effects (including false-positive results and anxiety) of rapid versus standard HIV testing in asymptomatic pregnant women? Key Question 3a. What is the effectiveness of newer antiretroviral regimens for reducing mother-to- child transmission? Key Question 3b. What are the effects of antiretroviral regimens in pregnant, HIV-positive women on long-term maternal morbidity, mortality, or quality of life? Key Question 3c. What are the harms (including longer-term harms) to the mother or child associated with antiretroviral therapy during pregnancy?